L914-0293 Screening compound: N-{2-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]ethyl}-3-[(2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)methyl]-1,2,4-oxadiazole-5-carboxamide

L914-0293 Screening compound: N-{2-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]ethyl}-3-[(2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)methyl]-1,2,4-oxadiazole-5-carboxamide
L914-0293 Screening compound: N-{2-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]ethyl}-3-[(2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)methyl]-1,2,4-oxadiazole-5-carboxamide alternative view

Chemical Structure Depiction of ChemDiv screening compound L914-0293
N-{2-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]ethyl}-3-[(2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)methyl]-1,2,4-oxadiazole-5-carboxamide

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

L914-0293

Molecular Formula

C24H25ClN6O4 (C24 H25 ClN6 O4)

Compound Name

N-{2-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]ethyl}-3-[(2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)methyl]-1,2,4-oxadiazole-5-carboxamide

IUPAC name

N-{2-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]ethyl}-3-[(2-oxo-23-dihydro-13-benzoxazol-3-yl)methyl]-124-oxadiazole-5-carboxamide

SMILES

Cc(ccc(Cl)c1)c1N1CCN(CCNC(c2nc(CN(c(cccc3)c3O3)C3=O)no2)=O)CC1

InChI

InChI=1S/C24H25ClN6O4/c1-16-6-7-17(25)14-19(16)30-12-10-29(11-13-30)9-8-26-22(32)23-27-21(28-35-23)15-31-18-4-2-3-5-20(18)34-24(31)33/h2-7,14H,8-13,15H2,1H3,(H,26,32)

InChI Key

FPWGCZZXENWAAU-UHFFFAOYSA-N

MDL Number (MFCD)

MFCD27486285

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

496.95

Hydrogen Bond Acceptors Count

9.00

Hydrogen Bond Donors Count

1.00

Rotatable Bond Count

8.00

Number of Nitrogen and Oxygen Atoms

10

Partition Coefficient, logP

3.240

Distribution Coefficient, logD

2.868

Water Solubility, LogSw

-3.81

Polar Surface Area

87.203

Acid Dissociation Constant (pKa)

12.23

Base Dissociation Constant (pKb)

7.53

Number of Chiral Centers

0.00

Percent sp3 carbon bonding

33.30

L914-0293 in Drug Discovery

Included in Screening Libraries

300k Representative Compounds Library (Bemis-Murcko Clustering Algorithm) (286253 compounds)

GPCR Targeted Library (31838 compounds)

PPI Inhibitors Tripeptide Mimetics (23972 compounds)

Peptidomimetic Library (37031 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Musculoskeletal
  • Respiratory tract
  • Nervous system
  • Congenital
  • Skin
  • Metabolic
  • Endocrine
Targets:
  • GPCR
Mechanism of action:
  • Receptor's ligands
  • PPI modulators
  • PPI modulators
Structure:
  • Mimetics
  • Mimetics

References: we are preparing a list of scientific research reports with L914-0293 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound L914-0293?
Check Price and Availability of L914-0293, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of L914-0293 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for L914-0293
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for L914-0293
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of L914-0293 available by request